

Registered Office: A-109 Express Apartments, Lakdi ka Pool, Hyderabad - 500004

Corporate Office: 5th floor, Prestige Phoenix, 1405, Uma Nagar, Begumpet, Hyderabad - 500016 +91 8688825013 • info@bankabio.com • www.bankabio.com • CIN: L90001TG2012PLC082811

An ISO 9001-2015-14001-2015-45001-2018 Company

BBL/SECT/32/2024-25

Date: 9 August 2024

To,
The Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051

NSE Symbol: BANKA

Sub: Update on Approval on Disinvestment.

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 vide our letter BBL/SECT/18/2024-25 dated 4 July 2024

This is with reference to our letter BBL/SECT/18/2024-25 dated 4 July 2024, intimating approval of Board of Directors with respect to disinvestment in Enzotech Solutions Private Limited, wholly-owned subsidiary by sale of 100% equity share capital held in wholly-owned subsidiary, subject to approval of members of the Company.

In this regard, please note that the members of the Company in the 12th Annual General Meeting held on 8 August 2024 (the Voting Results of which have been declared today, i.e., 9 August 2024) have approved for disinvestment in Enzotech Solutions Private Limited, wholly-owned subsidiary by sale of 100% equity share capital held in wholly-owned subsidiary.

Upon completion of aforesaid transaction, Enzotech Solutions Private Limited, shall cease to be a "wholly-owned subsidiary" to the Company.

The details, as required under Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular № SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13 July 2023 for above disclosure attached herewith, as Annexure.

Kindly take the same on record.

Thank you,

For Banka BioLoo Limited

Nitika Lakhotia Company Secretary & Compliance Officer

Encl: As above



Annexure: Disinvestment in Enzotech Solutions Private Limited,

wholly-owned subsidiary

The amount and percentage of the turnover or	Total Income: Rs. 239.46 Lakhs;
revenue or income and net worth contributed	% of Income of Company: 4.72 %
by such unit or division or undertaking or	7
subsidiary or associate company of the listed	Networth: Rs. 294.42 Lakhs;
entity during the last financial year;	·
	% of Networth of Company: 7.15 %
Date on which the agreement for sale has been	Pursuant to approval obtained by the members
entered into;	of the Company at the 12 th Annual General Meeting of the Company held on Thursday, 8
	August 2024, the Company shall enter into a
	Share Purchase Agreement with identified
	buyer(s), under applicable law.
	, , , <u>, , , , , , , , , , , , , , , , </u>
The expected date of completion of	Within six months from the date of approval of
sale/disposal;	the members of the Company, i.e., within six
	months from 8 August 2024.
	11 11 7 10 20 1 1
Consideration received from such	At a price, not less than Rs. 10.08 per share (face
sale/disposal;	value Rs. 10 per share), for an aggregate
	consideration of Rs. 4,41,45,980 (Rupees Four
	Crores Forty-One Lakhs Forty-Five Thousand
	Nine Hundred and Eighty Only) as determined
	by valuation report for sale of 100% Equity Share
	Capital held in Enzotech Solutions Private
	Limited.
Brief details of buyers and whether any of the	Yet to be identified.
buyers belong to the promoter/ promoter group/group companies. If yes, details	
thereof;	
Whether the transaction would fall within	No
related party transactions? If yes, whether the	
same is done at "arm's length";	
Whether the sale, lease or disposal of the	Not Applicable
undertaking is outside Scheme of	
Arrangement? If yes, details of the same	
including compliance with regulation 37A of	
LODR Regulations;	
Additionally, in case of a slump sale,	Not Applicable
indicative disclosures provided for	
amalgamation/merger, shall be disclosed by	
the listed entity with respect to such slump	
sale.	